Contact Information:
Wanyi Tai, Ph.D.
Mailing address: N530B William H. Foege Building, 3720 15th Ave NE Seattle, WA, 98195-5061.
Phone: 206-543-0321
E-mail:wt8q9@umkc.edu
Education
09/2000—06/2004
B.S., Pharmacy, China Pharmaceutical University
09/2004—06/2007
M.S., Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
08/2007—08/2012
Ph.D., Pharmaceutical Sciences, University of Missouri-Kansas City
09/2012—11/2013
Postdoc., Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University
12/2013—present
Senior postdoctoral fellow, University of Washington
B.S., Pharmacy, China Pharmaceutical University
09/2004—06/2007
M.S., Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
08/2007—08/2012
Ph.D., Pharmaceutical Sciences, University of Missouri-Kansas City
09/2012—11/2013
Postdoc., Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University
12/2013—present
Senior postdoctoral fellow, University of Washington
Experimental skills
Organic synthesis, polymer synthesis, RNA isolation, real time PCR, molecular cloning, recombinant protein expressing and purification, western blotting, xenograft mode establishment (breast cancer and prostate cancer models), siRNA transfection, liposome preparation, NMR, HPLC, HPLC-MS/MS analysis, radioactive cellular uptake, IC50 profiling, ELISA, cancer cell culture, confocal microscopy.
Research experience
Post Doctoral Research:
-Develop a glucose oxidase mediated, glucose responsive polymersome nanovesicle for in vivo insulin delivery. : Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, 2012-2013
-Fold graft copolymer into nanoparticles for in vivo cancer therapy through codelivery of camptothecin and doxorubicin.
Doctoral Research:
-Design and synthesis of peptide-drug conjugates for prostate cancer therapy. : Division of Pharmaceutical Sciences, University of Missouri-Kansas City, 2007-2012
-Evaluation of the expression profile and functional activity of peptide transporters in prostate cancer cells.
-Development of polymer rapamycin conjugates for cancer therapy.
-Analysis of the combinational treatment effect of HER2 and VEGF siRNAs on breast cancer cells.
-Identification of HER2 specific peptide by phage display.
Master’s Research:
-Synthesis of ring-open bengamide analogue library and analysis of its Structure Activity Relationship (SAR). : National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2004-2007
-Facile synthesis of versatile functionalized amino caprolactams using RCM reactions.
-Develop a glucose oxidase mediated, glucose responsive polymersome nanovesicle for in vivo insulin delivery. : Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, 2012-2013
-Fold graft copolymer into nanoparticles for in vivo cancer therapy through codelivery of camptothecin and doxorubicin.
Doctoral Research:
-Design and synthesis of peptide-drug conjugates for prostate cancer therapy. : Division of Pharmaceutical Sciences, University of Missouri-Kansas City, 2007-2012
-Evaluation of the expression profile and functional activity of peptide transporters in prostate cancer cells.
-Development of polymer rapamycin conjugates for cancer therapy.
-Analysis of the combinational treatment effect of HER2 and VEGF siRNAs on breast cancer cells.
-Identification of HER2 specific peptide by phage display.
Master’s Research:
-Synthesis of ring-open bengamide analogue library and analysis of its Structure Activity Relationship (SAR). : National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2004-2007
-Facile synthesis of versatile functionalized amino caprolactams using RCM reactions.
Teaching experience
Teaching Assistant, Medicinal Chemistry II (PHARM 7344), University of Missouri-Kansas City
Award and honors
2010 Outstanding Leadership Award, University of Missouri-Kansas City
2003 The National Scholarship
2003 The National Scholarship
Professional memberships
2009-2011 American Association of Pharmaceutical Scientists
2010-2011 Controlled Release Society
2010-Present The Rho Chi Society
2010-2011 Controlled Release Society
2010-Present The Rho Chi Society
Publications
1. Wanyi Tai, Zhijin Chen, Ashutosh Barve, Zhonghua Peng, Kun Cheng*. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharmaceutical Research 2013 Sep. 26 (Epub ahead of print)
2. Wanyi Tai, Zhijin Chen, Kun Cheng*. Expression profile and functional activity of peptide transporters in prostate cancer cells. Molecular Pharmaceutics 2013, 10(2): 477-487
3. Bin Qin, Wanyi Tai, Ravi S Shukla, Kun Cheng*. Identification of a LNCaP-Specific Binding Peptide Using Phage Display. Pharmaceutical Research 2011, 28(10): 2422-2434
4. Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng*. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics 2011, 8(3):901-912 (Highlighted by SciBX, Global Medical Discovery and NewsRx etc)
5. Rubi Mahato, Wanyi Tai, Kun Cheng*. Prodrug for improving tumor targetability and efficiency. Advanced Drug Delivery Review 2011, 63(8):659-670
6. Wanyi Tai, Rubi Mahato, Kun Cheng*. The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release 2010, 146(3):264-275
7. Wanyi Tai, Bin Qin, Kun Cheng*. Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF. Molecular Pharmaceutics 2010, 7(2):543-556
8. Wan-Yi Tai†, Run-Tao Zhang†, Yi-Ming Ma, Min Gu, Gang Liu, Jia Li, Fa-Jun Nan*. Design, Synthesis, and Biological Evaluation of Ring‐Opened Bengamide Analogues. ChemMedChem 2011, 6(9): 1555-1558. († These authors contributed equally).
9. Gang Liu†, Yi-Ming Ma†, Wan-Yi Tai †, Chuan-Ming Xie, Yu-Lin Li, Jia Li and Fa-Jun Nan*. (2008). Design, Synthesis, and Biological Evaluation of Caprolactam-Modified Bengamide Analogues. ChemMedChem 2008, 3, 74–78. († These authors contributed equally).
10. Gang Liu, Wan-Yi Tai, Yu-Lin Li and Fa-Jun Nan*. (2006) Facile synthesis of versatile functionalized amino caprolactams using RCM reactions of α-amino acrylamide . Tetrahedron Letters, 2006, 47, 3295-3298
2. Wanyi Tai, Zhijin Chen, Kun Cheng*. Expression profile and functional activity of peptide transporters in prostate cancer cells. Molecular Pharmaceutics 2013, 10(2): 477-487
3. Bin Qin, Wanyi Tai, Ravi S Shukla, Kun Cheng*. Identification of a LNCaP-Specific Binding Peptide Using Phage Display. Pharmaceutical Research 2011, 28(10): 2422-2434
4. Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng*. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics 2011, 8(3):901-912 (Highlighted by SciBX, Global Medical Discovery and NewsRx etc)
5. Rubi Mahato, Wanyi Tai, Kun Cheng*. Prodrug for improving tumor targetability and efficiency. Advanced Drug Delivery Review 2011, 63(8):659-670
6. Wanyi Tai, Rubi Mahato, Kun Cheng*. The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release 2010, 146(3):264-275
7. Wanyi Tai, Bin Qin, Kun Cheng*. Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF. Molecular Pharmaceutics 2010, 7(2):543-556
8. Wan-Yi Tai†, Run-Tao Zhang†, Yi-Ming Ma, Min Gu, Gang Liu, Jia Li, Fa-Jun Nan*. Design, Synthesis, and Biological Evaluation of Ring‐Opened Bengamide Analogues. ChemMedChem 2011, 6(9): 1555-1558. († These authors contributed equally).
9. Gang Liu†, Yi-Ming Ma†, Wan-Yi Tai †, Chuan-Ming Xie, Yu-Lin Li, Jia Li and Fa-Jun Nan*. (2008). Design, Synthesis, and Biological Evaluation of Caprolactam-Modified Bengamide Analogues. ChemMedChem 2008, 3, 74–78. († These authors contributed equally).
10. Gang Liu, Wan-Yi Tai, Yu-Lin Li and Fa-Jun Nan*. (2006) Facile synthesis of versatile functionalized amino caprolactams using RCM reactions of α-amino acrylamide . Tetrahedron Letters, 2006, 47, 3295-3298
Book Chapter
1. Wanyi Tai, Kun Cheng*. (2013) “Advanced drug delivery in cancer therapy” In Mitra AK, Lee C. Cheng K. edits “Advanced drug delivery” Wiley-Blackwell, John Wiley & Sons, Inc.
1. Wanyi Tai, Kun Cheng*. (2013) “Advanced drug delivery in cancer therapy” In Mitra AK, Lee C. Cheng K. edits “Advanced drug delivery” Wiley-Blackwell, John Wiley & Sons, Inc.
Patent
Fa-Jun Nan, Jia Li, Jian Ding, Gang Liu, Chuan-Ming Xie, Yi Chen, Wan-Yi Tai, Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof. International application No. PCT/CN2008/001996
Conference abstract
1. Wanyi Tai, Bin Qin, Kun Cheng. (2009) Inhibition of breast cancer cell growth via inhibiting HER-2 and VEGF using siRNA. AAPS National Biotechnology Conference. Abst. No. 000682.
2. Wanyi Tai, Kun Cheng. (2010) Development of a Cell Specific Peptide-Drug Conjugate for Prostate Cancer Therapy. The 37th Annual Meeting & Exposition of the Controlled Release Society.
3. Bin Qin, Wanyi Tai, Kun Cheng. (2011) Synthesis of a peptide-siRNA conjugate for targeted delivery to breast cancer cells. 2011 AAPS Annual Meeting and Exposition.
2. Wanyi Tai, Kun Cheng. (2010) Development of a Cell Specific Peptide-Drug Conjugate for Prostate Cancer Therapy. The 37th Annual Meeting & Exposition of the Controlled Release Society.
3. Bin Qin, Wanyi Tai, Kun Cheng. (2011) Synthesis of a peptide-siRNA conjugate for targeted delivery to breast cancer cells. 2011 AAPS Annual Meeting and Exposition.
